

# CK HMW + p63 + AMACR (RM)

Prediluted Multiplex Antibody Reagent  
901-3154DS-040719

**BIOCARE**  
M E D I C A L

Catalog Number:	API 3154DS AA, H	IPI 3154DS G10	OAI 3154 T60	VTMR 3154 G20
Description:	6.0, 25 mL, RTU	10 mL, RTU	60 tests, RTU	20 mL, RTU
Dilution:	Ready-to-use	Ready-to-use	Ready-to-use	Ready-to-use
Diluent:	N/A	N/A	N/A	N/A

## Intended Use:

For In Vitro Diagnostic Use

CK HMW + p63 + AMACR (RM) is a cocktail of mouse monoclonal and rabbit monoclonal antibodies that is intended for laboratory use in the qualitative identification of high molecular weight cytokeratin (CK 1, 5, 10, 14), p63 and AMACR proteins by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

## Summary and Explanation:

High molecular weight cytokeratins are expressed in a variety of normal and neoplastic epithelial tissues (1). In prostate, CK HMW [34βE12] has been shown to be a useful marker of basal cells of normal glands and prostatic intraepithelial neoplasia (PIN), a precursor lesion to prostatic adenocarcinoma; whereas invasive prostatic adenocarcinoma typically lacks a basal cell layer (2-4).

p63, a homolog of the tumor suppressor p53, has been identified in proliferating basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium and prostate (5). p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate (6).

α-Methylacyl coenzyme A racemase (AMACR), also known as P504S, is a peroxisomal and mitochondrial enzyme that plays a role in bile acid synthesis and β-oxidation of branched chain fatty acids (7). AMACR was initially identified from a cDNA library as a gene that is overexpressed in human prostate cancer; with little or no expression in normal prostate (8,9). In immunohistochemistry, AMACR has been shown to be a specific marker of prostatic adenocarcinoma (8-11). Additionally, prostate glands involved in PIN have been found to express AMACR, whereas AMACR was nearly undetectable in benign glands (11,12).

Studies have shown that combinations of CK HMW [34βE12], p63, and/or AMACR may be useful in the evaluation of normal prostate glands, PIN and prostatic adenocarcinoma (13,14).

U.S. Patent 8,603,765 and patents pending.

## Principle of Procedure:

This product is a primary antibody cocktail of mouse and rabbit antibodies, which may be used in a Multiplex IHC staining procedure to produce a two-color stain. Following application of the primary antibody cocktail to the tissue sample, detection is performed by separate secondary antibodies specific for each species (i.e. mouse or rabbit) of the primary antibody cocktail, which are conjugated to horseradish peroxidase (HRP) or alkaline phosphatase (AP) enzymes. Visualization is accomplished by the application of chromogenic substrates (DAB and Red), which are enzymatically activated (by HRP or AP, respectively) to produce a colored reaction product at the antigen site. The specimen may be counterstained and coverslipped. Results are interpreted using a light microscope.

## Reagent Provided:

CK HMW + p63 + AMACR (RM)\* is provided as a prediluted antibody cocktail of anti-CK HMW, anti-p63 and anti-AMACR antibodies in buffer with carrier protein and preservative. \*Product formerly known as PIN-4®

Antibody	anti-CK HMW	anti-p63	anti-AMACR
Clone	34βE12	4A4	13H4
Source	Mouse monoclonal	Mouse monoclonal	Rabbit monoclonal
Isotype	IgG1/kappa	IgG2a/kappa	IgG
Epitope/Antigen	CK HMW	p63	AMACR
Cellular Localization	Cytoplasmic	Nuclear	Cytoplasmic
Staining	Brown (DAB)	Brown (DAB)	Red

## Storage and Stability:

Store at 2°C to 8°C. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date.

## Known Applications:

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

**Species Reactivity:** Human; others not tested

**Positive Tissue Control:** Normal prostate and prostatic adenocarcinoma

## Protocol Recommendations (VALENT® Automated Slide Staining Platform):

VTMR3154 is intended for use with the VALENT. Refer to the User Manual for specific instructions for use. Protocol parameters in the Protocol Manager should be programmed as follows:

**Deparaffinization:** Deparaffinize for 8 minutes with Val DePar.

**Pretreatment:** Perform heat retrieval at 98°C for 60 minutes using Val AR-Hi pH, 5X (use at 1X).

**Peroxidase Block:** Block for 5 minutes with Val Peroxidase Block.

**Protein Block:** Incubate for 10 minutes with Val Background Block.

**Primary Antibody:** Incubate for 30 minutes.

**Double Stain Detection:** Incubate for 30 minutes using Val Plex 2.

**Chromogen (1):** Incubate for 5 minutes with Val DAB.

**Chromogen (2):** Incubate for 15 minutes with Val Fast Red.

**Counterstain:** Counterstain for 5 minutes with Val Hematoxylin.

## Protocol Recommendations (intelliPATH FLX® and manual use):

**Peroxide Block:** Block for 5 minutes with Peroxidized 1.

**Pretreatment:** Perform heat retrieval using Diva Decloaker. Refer to the Diva Decloaker product data sheet for specific instructions.

**Protein Block:** Incubate for 10 minutes at RT with Background Punisher.

**Primary Antibody:** Incubate for 30 minutes at RT.

**Double Stain Detection:** Incubate for 30 minutes at RT using MACH 2 Double Stain 2.

**Chromogen (1):** Incubate for 5 minutes at RT with Betazoid DAB.

**Chromogen (2):** Incubate for 5-7 minutes at RT with Warp Red. Rinse with deionized water.

**Counterstain:** Counterstain with hematoxylin. Rinse with deionized water. Apply Tacha's Bluing Solution for 1 minute. Rinse with deionized water.



60 Berry Drive  
Pacheco, CA 94553  
USA



Rev: 062117

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080

EC REP EMERGO EUROPE  
Prinsessegracht 20  
2514 AP The Hague  
The Netherlands

## CK HMW + p63 + AMACR (RM)

Prediluted Multiplex Antibody Reagent  
901-3154DS-040719

**BIOCARE**  
M E D I C A L

### **Protocol Recommendations (intelliPATH FLX and manual use)**

#### **Cont'd:**

#### **intelliPATH FLX Automated Slide Stainer:**

IPI3154DS is intended for use with the intelliPATH FLX. Refer to the User Manual for specific instructions for use. When using the intelliPATH FLX, peroxide block with intelliPATH FLX Peroxidase Blocking Reagent (IPB5000) may be performed following heat retrieval.

#### **Technical Note:**

This antibody, for intelliPATH FLX and manual use, has been optimized for use with intelliPATH Multiplex Secondary Reagent 2 and MACH 2 Double Stain 2. Use TBS buffer for washing steps.

### **Protocol Recommendations (ONCORE™ Automated Slide Staining System):**

OAI3154 is intended for use with the ONCORE. Refer to the User Manual for specific instructions for use. Protocol parameters in the Protocol Editor should be programmed as follows:

**Protocol Name:** HMW p63 AMACR

**Protocol Template (Description):** Multiplex 2 Template 1

**Dewaxing (DS Option):** DS Buffer

**Antigen Retrieval (AR Option):** AR2, low pH; 101°C

**Reagent Name, Time, Temp.:** HMW p63 AMACR, 30 min., 25°C

#### **Limitations:**

The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions.

#### **Quality Control:**

Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2) CLSI Wayne, PA USA (www.clsi.org). 2011

#### **Precautions:**

1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN<sub>3</sub>) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (15)
2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water. (16)
3. Microbial contamination of reagents may result in an increase in nonspecific staining.
4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.
5. Do not use reagent after the expiration date printed on the vial.
6. The SDS is available upon request and is located at <http://biocare.net>.

#### **Troubleshooting:**

Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.

#### **References:**

1. Moll R, *et al.* The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultures cells. *Cell.* 1982 Nov; 31(1):11-24.
2. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. *Mod Pathol.* 2004 Mar; 17(3):360-79.
3. Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. *J Clin Pathol.* 2007 Jan; 60(1):35-42.
4. Shah RB, *et al.* Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. *Am J Surg Pathol.* 2002 Sep; 26(9):1161-8.
5. Yang A, *et al.* p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. *Mol Cell.* 1998 Sep; 2(3):305-16.
6. Signoretti S, *et al.* p63 is a prostate basal cell marker and is required for prostate development. *Am J Pathol.* 2000 Dec; 157(6):1769-75.
7. Ferdinandusse S, *et al.* Subcellular localization and physiological role of alphas-methylacyl-CoA racemase. *J Lipid Res.* 2000 Nov; 41(11):1890-6.
8. Xu J, *et al.* Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. *Cancer Res.* 2000 Mar 15; 60(6):1677-82.
9. Rubin MA, *et al.* alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. *JAMA.* 2002 Apr 3; 287(13):1662-70.
10. Luo J, *et al.* Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. *Cancer Res.* 2002 Apr 15; 62(8):2220-6.
11. Zhou M, *et al.* Alpha-Methylacyl-CoA racemase: a novel tumor marker overexpressed in several human cancers and their precursor lesions. *Am J Surg Pathol.* 2002 Jul; 26(7):926-31.
12. Wu CL, *et al.* Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. *Hum Pathol.* 2004 Aug; 35(8):1008-13.
13. Shah RB, *et al.* Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations. *Am J Clin Pathol.* 2004 Oct; 122(4):517-23.
14. Sung MT, *et al.* Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy. *Hum Pathol.* 2007 Feb; 38(2):332-41.
15. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."
16. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.



60 Berry Drive  
Pacheco, CA 94553  
USA



Rev: 062117

Tel: 800-799-9499 | [www.biocare.net](http://www.biocare.net) | Fax: 925-603-8080

EC REP EMERGO EUROPE

Prinsessegracht 20  
2514 AP The Hague  
The Netherlands